(R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B.

Article Details

Citation

Copy to clipboard

Sterling J, Veinberg A, Lerner D, Goldenberg W, Levy R, Youdim M, Finberg J

(R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B.

J Neural Transm Suppl. 1998;52:301-5.

PubMed ID

9564630 [ View in PubMed

]

Abstract

(+)-N-Propargyl-1-aminoindan (rasagiline) and a series of derivatives have been synthesized and screened for monoamine oxidase inhibitory activity. Rasagiline and several analogues were found be highly selective and potent inhibitors of the B form of the enzyme in contrast to the levorotatory enantiomer which was not active. The results indicate that rasagiline has potential for the treatment of Parkinson's Disease. This compound is currently under development for that indication.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
N-Propargyl-1(S)-Aminoindan	Amine oxidase [flavin-containing] B	Protein	Humans	Unknown	Inhibitor	Details

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
N-Propargyl-1(S)-Aminoindan	Amine oxidase [flavin-containing] B	Protein	Humans	Unknown	Inhibitor	Details